CO2022008272A2 - Agentes de unión a ilt3 y métodos de uso de los mismos - Google Patents

Agentes de unión a ilt3 y métodos de uso de los mismos

Info

Publication number
CO2022008272A2
CO2022008272A2 CONC2022/0008272A CO2022008272A CO2022008272A2 CO 2022008272 A2 CO2022008272 A2 CO 2022008272A2 CO 2022008272 A CO2022008272 A CO 2022008272A CO 2022008272 A2 CO2022008272 A2 CO 2022008272A2
Authority
CO
Colombia
Prior art keywords
binding agents
methods
same
ilt3
ilt3 binding
Prior art date
Application number
CONC2022/0008272A
Other languages
English (en)
Inventor
Yan Wang
Suzanne Christine Crawley
Jer-Yuan Hsu
Daniel David Kaplan
Betty Chan Li
Vicky Yi-Bing Lin
Seth Malmersjö
Kevin James Paavola
Julie Michelle Roda
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CO2022008272A2 publication Critical patent/CO2022008272A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a ILT3, incluido ILT3 humano, así como composiciones que comprenden los agentes de unión y métodos para su uso. La divulgación también proporciona polinucleótidos relacionados y vectores que codifican los agentes de unión y células que comprenden los agentes de unión.
CONC2022/0008272A 2019-12-19 2022-06-13 Agentes de unión a ilt3 y métodos de uso de los mismos CO2022008272A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950434P 2019-12-19 2019-12-19
PCT/US2020/065642 WO2021127200A1 (en) 2019-12-19 2020-12-17 Ilt3-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022008272A2 true CO2022008272A2 (es) 2022-08-30

Family

ID=74554203

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008272A CO2022008272A2 (es) 2019-12-19 2022-06-13 Agentes de unión a ilt3 y métodos de uso de los mismos

Country Status (16)

Country Link
US (2) US11760802B2 (es)
EP (1) EP4077394A1 (es)
JP (1) JP2023507110A (es)
KR (1) KR20220130671A (es)
CN (2) CN114901691A (es)
AR (1) AR120822A1 (es)
AU (1) AU2020405036A1 (es)
BR (1) BR112022011790A2 (es)
CA (1) CA3164642A1 (es)
CL (1) CL2022001622A1 (es)
CO (1) CO2022008272A2 (es)
IL (1) IL293869A (es)
MX (1) MX2022007288A (es)
PE (1) PE20221263A1 (es)
TW (1) TW202136304A (es)
WO (1) WO2021127200A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240038769A (ko) * 2021-07-28 2024-03-25 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
US20230220076A1 (en) * 2021-12-21 2023-07-13 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
WO2023192850A1 (en) 2022-03-29 2023-10-05 Ngm Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
WO2023209716A1 (en) 2022-04-25 2023-11-02 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0644877B2 (ja) 1986-12-26 1994-06-15 寳酒造株式会社 抗ヒト・フイブロネクチンモノクロ−ナル抗体
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
AU2002345878A1 (en) 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
WO2005017102A2 (en) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2006036813A2 (en) 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
WO2013181438A2 (en) 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
SI2992017T1 (sl) 2013-05-02 2021-04-30 Anaptysbio, Inc. Protitelesa, usmerjena proti programirani smrti-1 (PD-1)
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
RU2017119185A (ru) 2014-11-05 2018-12-05 Дженентек, Инк. Антитела против fgfr2/3 и способы их применения
CA2976130A1 (en) 2015-02-11 2016-08-18 University Health Network Methods and compositions for modulating lilr proteins
JP6730996B2 (ja) 2015-03-06 2020-07-29 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP2018025554A (ja) 2016-07-29 2018-02-15 国立大学法人東北大学 炎症性疾患のマーカー
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018089300A1 (en) 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ilt3 ligand
WO2018148494A1 (en) 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CN111032025A (zh) 2017-06-20 2020-04-17 居里研究所 Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途
EP3710479A2 (en) 2017-11-17 2020-09-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
EP3740224A4 (en) 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
US20220324950A1 (en) 2019-08-13 2022-10-13 Tohoku University Immune checkpoint inhibitor, therapeutic agent for immune checkpoint-related disease, immunosuppressant, anti-fibronectin antibody or derivative thereof, fibronectin analog, kit for detecting fibronectin or partial protein thereof, and method for detecting fibronectin or partial protein thereof

Also Published As

Publication number Publication date
EP4077394A1 (en) 2022-10-26
KR20220130671A (ko) 2022-09-27
WO2021127200A8 (en) 2022-07-14
CL2022001622A1 (es) 2023-03-24
WO2021127200A1 (en) 2021-06-24
US11760802B2 (en) 2023-09-19
MX2022007288A (es) 2022-07-12
US20210221887A1 (en) 2021-07-22
PE20221263A1 (es) 2022-08-16
JP2023507110A (ja) 2023-02-21
CA3164642A1 (en) 2021-06-24
CN114901691A (zh) 2022-08-12
BR112022011790A2 (pt) 2022-08-30
IL293869A (en) 2022-08-01
CN115746138A (zh) 2023-03-07
US20240043533A1 (en) 2024-02-08
AR120822A1 (es) 2022-03-23
TW202136304A (zh) 2021-10-01
AU2020405036A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CO2021008568A2 (es) Anticuerpos que se unen a cd3
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
CL2020002522A1 (es) Agentes de unión a c3 y métodos para su uso
ECSP21090414A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
UY33274A (es) Proteínas de unión a basigina
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas